Oranda Therapeutics

Oranda Therapeutics is a newly established rare disease company that has entered into exclusive negotiations for a new drug, currently in Phase 2b trials for the treatment of hyperphagia in Prader-Willi Syndrome (PWS). Based on the study results, the drug is planned to enter pivotal Phase 3 trials in 2025.